Research is ongoing to find alternatives and adjuncts to cytarabine. Newer agents like clofarabine and decitabine, which are also nucleoside analogs, have shown promise in treating hematologic malignancies. Moreover, targeted therapies and immunotherapies are being explored to complement or replace traditional chemotherapy, offering potentially less toxic and more effective treatment options.
